Erythropoietin treatment of idiopathic myelofibrosis

M. A. Aloe Spiriti; R. Latagliata; G. Avvisati; V. Battistel; E. Montefusco; A. Spadea; M. C. Petti

Erythropoietin treatment of idiopathic myelofibrosis

M. A. Aloe Spiriti, R. Latagliata, G. Avvisati, V. Battistel, E. Montefusco, A. Spadea, M. C. Petti

Istituto Regina Elena

Research output: Contribution to journal › Article › peer-review

Abstract

Background. In order to determine whether recombinant human erythropoietin (rHuEPO) may play a role in treating anemia in idiopathic myelofibrosis (IMF), a pilot study using high doses of rHuEPO was conducted on patients with IMF. Methods and results. From September, 1990 to December, 1992, 7 patients (6 males and 1 female, median age 68 years) affected by IMF entered the trial. RHuEPO was administered subcutaneously 5 days a week at a dosage of 160 U/kg daily for three mouths. Out of 7 patients, 4 obtained a response. These responders received additional maintenance treatment with rHuEPO until relapse. Response duration was 6, 7, 10+, and 16 months, respectively. Treatment was well-tolerated. Conclusions. Our data suggest that rHuEPO may play a role in the treatment of anemia in some IMF patients.

Original language	English
Pages (from-to)	371-373
Number of pages	3
Journal	Haematologica
Volume	78
Issue number	6
Publication status	Published - 1993

Keywords

erythropoietin
idiopathic myelofibrosis

ASJC Scopus subject areas

Hematology

Cite this

@article{2a7646ecea6b498fb7463d4404d87078,

title = "Erythropoietin treatment of idiopathic myelofibrosis",

abstract = "Background. In order to determine whether recombinant human erythropoietin (rHuEPO) may play a role in treating anemia in idiopathic myelofibrosis (IMF), a pilot study using high doses of rHuEPO was conducted on patients with IMF. Methods and results. From September, 1990 to December, 1992, 7 patients (6 males and 1 female, median age 68 years) affected by IMF entered the trial. RHuEPO was administered subcutaneously 5 days a week at a dosage of 160 U/kg daily for three mouths. Out of 7 patients, 4 obtained a response. These responders received additional maintenance treatment with rHuEPO until relapse. Response duration was 6, 7, 10+, and 16 months, respectively. Treatment was well-tolerated. Conclusions. Our data suggest that rHuEPO may play a role in the treatment of anemia in some IMF patients.",

keywords = "erythropoietin, idiopathic myelofibrosis",

author = "{Aloe Spiriti}, {M. A.} and R. Latagliata and G. Avvisati and V. Battistel and E. Montefusco and A. Spadea and Petti, {M. C.}",

year = "1993",

language = "English",

volume = "78",

pages = "371--373",

journal = "Haematologica",

issn = "0390-6078",

publisher = "NLM (Medline)",

number = "6",

}

TY - JOUR

T1 - Erythropoietin treatment of idiopathic myelofibrosis

AU - Aloe Spiriti, M. A.

AU - Latagliata, R.

AU - Avvisati, G.

AU - Battistel, V.

AU - Montefusco, E.

AU - Spadea, A.

AU - Petti, M. C.

PY - 1993

Y1 - 1993

N2 - Background. In order to determine whether recombinant human erythropoietin (rHuEPO) may play a role in treating anemia in idiopathic myelofibrosis (IMF), a pilot study using high doses of rHuEPO was conducted on patients with IMF. Methods and results. From September, 1990 to December, 1992, 7 patients (6 males and 1 female, median age 68 years) affected by IMF entered the trial. RHuEPO was administered subcutaneously 5 days a week at a dosage of 160 U/kg daily for three mouths. Out of 7 patients, 4 obtained a response. These responders received additional maintenance treatment with rHuEPO until relapse. Response duration was 6, 7, 10+, and 16 months, respectively. Treatment was well-tolerated. Conclusions. Our data suggest that rHuEPO may play a role in the treatment of anemia in some IMF patients.

AB - Background. In order to determine whether recombinant human erythropoietin (rHuEPO) may play a role in treating anemia in idiopathic myelofibrosis (IMF), a pilot study using high doses of rHuEPO was conducted on patients with IMF. Methods and results. From September, 1990 to December, 1992, 7 patients (6 males and 1 female, median age 68 years) affected by IMF entered the trial. RHuEPO was administered subcutaneously 5 days a week at a dosage of 160 U/kg daily for three mouths. Out of 7 patients, 4 obtained a response. These responders received additional maintenance treatment with rHuEPO until relapse. Response duration was 6, 7, 10+, and 16 months, respectively. Treatment was well-tolerated. Conclusions. Our data suggest that rHuEPO may play a role in the treatment of anemia in some IMF patients.

KW - erythropoietin

KW - idiopathic myelofibrosis

UR - http://www.scopus.com/inward/record.url?scp=0027851312&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027851312&partnerID=8YFLogxK

M3 - Article

C2 - 8175031

AN - SCOPUS:0027851312

VL - 78

SP - 371

EP - 373

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 6

ER -

Erythropoietin treatment of idiopathic myelofibrosis

Abstract

Keywords

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this